Carlsmed Unveils Personalized Spine Platform, Targets $70M-$75.5M 2025 Revenue at Conference

Core Insights - Carlsmed has demonstrated strong early customer traction, expanding its user base by nearly 70% last year, ending with 253 trained surgeon users [1] - The company aims to improve outcomes and reduce costs in spine surgery through a personalized, data-driven technology platform [3] Financial Performance - Carlsmed generated $50.5 million in revenue in its first year as a public company, representing an 86% year-on-year growth [2][5] - The company projects revenue between $70 million and $75.5 million for the current year, indicating a 44% growth at the midpoint [2][5] - In Q4, Carlsmed reported revenue of "north of $15 million" with a gross margin of 76.5% [2][5] Technology and Innovation - The aprevo Technology Platform enables patient-specific 3D surgical planning, on-demand 3D-printed implants, and sterile single-use instruments across the surgical workflow [6][16] - The platform has reduced order-to-delivery times from about eight weeks to six days, enhancing operational efficiency [13] Clinical and Reimbursement Advantages - Two-year data published in the Global Spine Journal showed a 74% reduction in revision rates for patients treated with Carlsmed's personalized approach compared to traditional methods [4][9] - Carlsmed has received FDA Breakthrough Device Designation and secured New Technology Add-on Payment (NTAP) for its lumbar offering, providing significant incremental hospital payments [10][12] Market Focus and Expansion - Carlsmed is focused on the U.S. spine market, serving both lumbar and cervical segments, with an estimated annual addressable procedure volume of over 800,000 [7] - The company has recently expanded into cervical spine procedures, targeting specific patient populations with tailored implants [11][12] Operational Improvements - The company has implemented a "zero inventory" model for hospitals, allowing for on-demand delivery of sterile-packed instruments and implants [14] - Carlsmed has completed its first posterior minimally invasive bilateral approach using the aprevo platform, showcasing its commitment to innovation [14]